Know the Roles of Remdesivir and IL-6 Inhibitors for COVID-19

May 2020

You'll get questions about remdesivir or interleukin-6 (IL-6) inhibitors for hospitalized COVID-19 patients.

Remdesivir is an investigational IV antiviral with in vitro activity against the SARS-CoV-2 virus that causes COVID-19.

Observational data suggest improvements in oxygenation. And a recent trial in severe COVID-19 patients with pneumonia shows no benefit...but it was stopped early due to low enrollment.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote